Sino Biopharmaceutical 2020 Net Profit Grows to RMB2.77 Billion amid Adversity
Mar 23, 2021 17:09 HKT |  |
|
Ocumension Therapeutics (1477.HK) Announces 2020 Annual Results
Mar 20, 2021 10:10 HKT |  |
|
Milestone Development Achieved in Clinical Trials and Commercialization, Hua Medicine's Dorzagliatin Readying for NDA Submission
Mar 19, 2021 14:34 HKT |  |
|
Alvotech Completes Second Round of a US$100 Million Private Placement
Mar 15, 2021 17:38 HKT |  |
|
Size matters: Bimodal imaging receives nanoparticle enhancement
Mar 10, 2021 20:00 HKT |  |
|
Apollomics, Inc. Appoints Seasoned Healthcare Executive K. Peony Yu, M.D., as Chief Medical Officer
Mar 09, 2021 10:35 HKT |  |
|
Apollomics, Inc Announces Enrollment of First Patient in Phase 1 Clinical Trial of APL-106 (uproleselan injection) in China
Mar 04, 2021 11:30 HKT | |
|
Alvotech and Cipla Gulf Expand Partnership for Commercialization of Biosimilars in Australia and New Zealand
Mar 04, 2021 10:26 HKT | |
|
Maculus Therapeutix welcomes Privity, Prepares Capital Raise for Novel Drug Delivery Platform
Feb 19, 2021 07:00 HKT |  |
|
Suntrap Discovered 'LeSoleil' for COVID-19 and the Epidemic
Feb 14, 2021 20:00 HKT |  |
|
Cofttek, China's Largest Manufacturer of PEA, Draws Attention of Investors
Feb 14, 2021 01:00 HKT |  |
|
Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China and South Africa
Feb 12, 2021 13:00 HKT | |
|
Novamind Announces Strategic Investment in Bionomics to Support PTSD Clinical Trial
Feb 11, 2021 21:00 HKT |  |
|
Apollomics, Inc. and Iterion Therapeutics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Tegavivint in Greater China
Feb 11, 2021 11:00 HKT | |
|
Apollomics, Inc. and Edison Oncology Announce Licensing Agreement for Novel Protein Tyrosine Kinase Inhibitor Targeting Solid Tumors
Feb 10, 2021 10:10 HKT | |
|
Two Immigrants, One Unique Plan For A Biopharma
Feb 03, 2021 06:00 HKT | |
|
Lasting Antiviral Effect against Covid-19 virus (SARS-CoV-2) by TAKEX CLEAN EXTRA
Feb 02, 2021 11:00 HKT |  |
|
Shanghai Longyao Chief Scientist Professor Xuanming Yang published a research article on optimizing CAR-T cells function with independently expressed full-length OX40
Jan 29, 2021 08:00 HKT | |
|
China Biotech Services LY007 Cell Injection Obtained Clinical Trial Approval Letter
Jan 28, 2021 09:50 HKT | |
|
New benchmark set to deliver optimal osteoporosis care throughout Asia Pacific
Jan 28, 2021 07:00 HKT |  |
|